|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Par Pharmaceutical, Inc. |
|---|---|
| Collaborator: |
Quintiles |
| Information provided by: | Par Pharmaceutical, Inc. |
| ClinicalTrials.gov Identifier: | NCT00637572 |
Purpose
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections Unintended Weight Loss Cachexia Anorexia AIDS Wasting Syndrome HIV Wasting Syndrome |
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL Drug: Megestrol acetate oral suspension 40 mg/mL |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
| Official Title: | A Randomized, Open-Labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-Related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace) |
| Enrollment: | 63 |
| Study Start Date: | December 2004 |
| Study Completion Date: | June 2005 |
| Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Megestrol acetate oral suspension nanocrystal dispersion formulation
|
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
|
|
2: Active Comparator
Megestrol acetate oral suspension micronized formulation
|
Drug: Megestrol acetate oral suspension 40 mg/mL
Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Pennsylvania | |
| Drexel University College of Medicine | |
| Philadelphia, Pennsylvania, United States, 19102 | |
| India, Karnataka | |
| M.S. Ramaiah Medical College and Hospital | |
| Bangalore, Karnataka, India, 560054 | |
| Kasturba Medical College | |
| Mangalore, Karnataka, India, 575003 | |
| Victoria Hospital | |
| Bangalore, Karnataka, India, 560002 | |
| India, Maharashtra | |
| Ruby Hall Clinic and Grant Medical Foundation | |
| Pune, Maharashtra, India, 411001 | |
| South Africa, Ashwood | |
| St Mary's Hospital | |
| Private Bag, Ashwood, South Africa, 3605 | |
| South Africa, Bloemfontein | |
| Genclin Corporation, Clinical Trial Centre | |
| Westdene, Bloemfontein, South Africa, 9301 | |
| Quinta-research | |
| Pellissier, Bloemfontein, South Africa, 9317 | |
| South Africa, Johannesburg | |
| 40 Arthur Hobbs Street | |
| Boksburg, Johannesburg, South Africa, 1466 | |
| South Africa, Kwazulu Natal | |
| 6 Calypso Centre | |
| Richards Bay, Kwazulu Natal, South Africa, 3900 | |
| South Africa, Pretoria | |
| TrialTech Clinical Research | |
| Hatfield, Pretoria, South Africa, 0001 | |
| Eastmed Hospital | |
| Eastlynn, Pretoria, South Africa, 0186 | |
| Principal Investigator: | Jan Fourie, MD | 58 Ann Street, Dundee, KZ-Natal 3000, S. Africa |
More Information
| Responsible Party: | Par Pharmaceutical, Inc ( VP Clinical and Medical Affairs ) |
| Study ID Numbers: | PAR-002 |
| Study First Received: | March 11, 2008 |
| Last Updated: | April 1, 2008 |
| ClinicalTrials.gov Identifier: | NCT00637572 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Weight loss Cachexia Anorexia Megestrol acetate oral suspension Nanocrystal dispersion Nanocrystal technology Body weight changes |
AIDS wasting HIV wasting Emaciation Megace ES Megace Treatment Experienced |
|
Sexually Transmitted Diseases, Viral Slow Virus Diseases Signs and Symptoms, Digestive Contraceptive Agents Antineoplastic Agents HIV Wasting Syndrome Contraceptives, Oral Physiological Effects of Drugs Contraceptive Agents, Female Cachexia Reproductive Control Agents Infection Body Weight Signs and Symptoms Pathologic Processes |
Therapeutic Uses Syndrome Weight Loss Body Weight Changes Contraceptives, Oral, Synthetic Nutrition Disorders Retroviridae Infections Appetite Stimulants RNA Virus Infections Metabolic Diseases Disease Antineoplastic Agents, Hormonal Immune System Diseases Acquired Immunodeficiency Syndrome Central Nervous System Stimulants |